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The classical definition of a genetically engineered or
“transgenic” animal would be “those animals modified
by recombinant DNA (rDNA) techniques” according to
the U.S. Food and Drug Administration (United States
Food and Drug Administration, Guidance #187, 2009).
Thus, the introduction or deletion of any gene by using
recombinant DNA would fall into this category. Since
the first reports of stable germline transmission of inte-
grated DNA in 1982, hundreds of thousands of trans-
genic animals have been produced, the vast majority of
which are mice used in biomedical research. However,
there are also thousands of agrarian and aquaculture
species that have been produced for a wide variety of
purposes from production of human biopharmaceuticals,
xenotransplantation and to enhance economically
important production traits.
We can separate the transgenic animals produced in
our laboratory into 3 major classes; production agricul-
ture, biopharmaceutical production in milk and biome-
dical models of human disease. This brief review will
highlight some of those projects in each category.
Transgenic livestock in production agriculture
Production agriculture projects in our laboratory have
utilized RNA interference to enhance meat production
through improved muscle growth. Myostatin is a nega-
tive regulator of muscle cell proliferation during fetal
development. It is know that inactivating mutations in a
number of species, including cattle, develop a muscle
overgrowth phenotype [1]. Although the increased mus-
cle can be considered a positive trait, the increase in
dystocia related to the size of the calves at birth limit
the utilization of these naturally occurring myostatin
mutations in production agriculture. RNA interference
has been utilized to overexpress a short hairpin RNA
(shRNA) with homology to the myostatin mRNA in vivo.
Direct injection into the perivitelline space of bovine
zygotes with recombinant lentiviral vectors promoted the
efficient integration of the shRNA expression constructs
into the bovine genome. The expression and cellular pro-
cessing of the myostatin shRNA led to degradation of the
myostatin mRNA and an overt muscling phenotype in
transgenic cattle [2]. Subsequent studies in pigs also
show a significant increase in fetal pig weights compared
to transgenic controls. The advantage of this approach is
that shRNA mediated degradation of the myostatin
mRNA over a range of values, typically between 20-80%
of controls. This approach can be used to decrease the
production of myostatin in a way that may lead to
increase muscling without associated dystocia problems.
Enhanced resistance to endemic diseases, especially
where vaccination strategies are ineffective or difficult to
achieve, could dramatically increase the production capa-
city and thus the profitability of animal production sys-
tems. We have used RNAi to investigate host/pathogen
interactions by direct suppression of viral proteins or
immune system modulators, which decrease viral replica-
tion and improve disease resistance. Direct targeting of
viral mRNA can reduce but not eliminate vesicular sto-
matitis virus or equine infectious anemia virus in vitro
[3]. Likewise, suppression of the immunomodulatory
components of the innate immune system have shown
positive results, but not complete protection of the cells
from viral infection. Current and future work will con-
tinue to refine these efforts with the long term goal of
producing animals with enhanced innate immunity to a
wide variety of viral and bacterial pathogens. Short-term
investigations in collaboration with the USDA Plum
Island Animal Disease Center have focused on therapeu-
tic approaches to prevent spread of diseases such as Foot
and Mouth Disease Virus during outbreaks.
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Transgenic livestock for biopharmaceutical
production
Mammals have the remarkable ability to produce large
quantities of proteins in their mammary glands and
secrete these proteins during lactation. This natural pro-
tein production “factory” can be utilized to produce pro-
teins that benefit both animals and humans through
genetic engineering. By placing a mammary gland speci-
fic promoter in a position to express a protein of inter-
est, the mammary gland can be made to produce nearly
any protein desired [4]. Production of useful biopharma-
ceutical proteins in the milk of several species has been
demonstrated. Species such as mice, rabbits, pigs, goats
and cattle have all been utilized to produce proteins of
biomedical value in milk. This is a low cost, high yield
system that can be implemented to produce biopharma-
ceuticals without the hundreds of millions of dollars
necessary to build cell culture or bacterial processing
facilities. In partnership with rEVO Biologics our labora-
tory has reinitiated a project to produce a malaria vac-
cine antigen in the milk of goats.
In collaboration with rEVO Biologics, Texas A&M has
rederived a line of goats, originally produced through
pronuclear microinjection, that produce a tagged
malaria parasite protein exclusively in their milk. At the
beginning of this project, scientists at rEVO inserted a
modified portion of a malaria parasite protein (MSP142)
into mice and collected the milk. MSP142 was purified
and mixed with an adjuvant to create an immune
response that could mitigate a malaria exposure/challenge
[5]. This vaccine was tested in non-human primates and
effectively protected the animals from a lethal dose of
malaria parasite. Thus, it was clear that the MSP142 was
capable of producing effective vaccine. To increase pro-
duction, rEVO inserted rDNA encoding the same protein
into the genome of a dairy goat and produced animals
capable of making the exact same protein on a much lar-
ger scale. In fact, one goat during her lactation can pro-
duce enough MSP142 to produce approximately 1 million
doses of malaria vaccine. These goats can now be propa-
gated through natural or artificial insemination to expand
the herd. Ongoing research will establish whether the goat
derived material has the same biological activity as the
previously tested mouse derived antigen. If so, this repre-
sents a low cost method of producing high quality antigen
which can be readily purified to produce vaccine.
Transgenic livestock as biomedical models of
human disease
In addition to the benefits livestock animals bring to the
human population in terms of food and fiber, they also
represent interesting models to study diseases important
to both human and veterinary medicine. Although natu-
rally occurring genetic mutations have been discovered
that produce important models of human disease, the abil-
ity to specifically modulate gene expression in livestock
represents a unique opportunity to study gene function in
animals. Livestock, especially pigs, share a similar size and
physiology to humans and are important subjects for
study of potential disease therapies prior to undergoing
costly clinical trials. Our lab has begun to develop pigs as
biomedical models for human obesity and metabolic syn-
drome, by inducible tissue specific expression of trans-
genes delivered by recombinant retroviral vectors.
Retroviral vectors were utilized to produce the first
transgenic mice. Although these initial experiments were
successful, problems with germline transmission hindered
further utilization for many years. Since those initial stu-
dies, a multitude of innovations have produced a new class
of recombinant, replication incompetent lentiviruses that
have overcome many of the initial limitations. These
highly modified and updated vectors are rapidly being uti-
lized in human gene therapy trials with good results.
Thus, lentiviral vectors are recognized as a safe and effec-
tive means for transduction of a number of cell types
including gametes and embryos. Microinjection of concen-
trated lentiviral particles into the perivitelline space of live-
stock oocytes or zygotes can produce genetically modified
embryos at high rates [2,6]. In the context of transgenic
livestock, lentiviral mediated delivery of transgenes repre-
sents a unique regulatory obstacle due the nature of the
integrated construct. Thus, in the short term, utility as a
vector for agricultural applications would appear limited at
best. Nonetheless, many biomedical applications can uti-
lize the ability of these vectors to package and deliver
transgenes into oocytes or zygotes to efficiently produce
genetically modified embryos for subsequent transfer and
production of offspring.
Our laboratory is currently developing new recombinant
lentiviruses capable of tetracycline inducible, tissue specific
expression of transgenes in livestock species. In contrast to
the murine model, there are currently limited options for
this type of transgene expression systems in swine or
other livestock species. These constructs can be designed
to overexpress proteins, suppress endogenous translation
via RNAi or both. The goal of the current work is to target
stearyl Co-A desaturase (SCD-1), an enzyme that is a key
regulatory element in lipid biosynthesis [7]. By altering
expression of SCD-1 in a tissue and inducible way, we can
control tissue steatosis. Muscle and hepatic steatosis is
detrimental to human health, but is considered a valuable
production trait in cattle muscle (marbling). Thus, the ani-
mals produced in these studies will have utility as biome-
dical models, but also could be useful in livestock
production systems. The further refinement of inducible,
tissue specific methods of genetic engineering offer excep-
tional opportunities for production of biomedical models
of human disease and livestock production.
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Summary
As new genetic engineering technologies develop, the abil-
ity to effectively and efficiently engineer the genome of
livestock species will improve. Recently the utilization of
site specific nucleases (TALEN and ZFN) and RNA guided
nucleases (CRISPR/Cas9) have revolutionized the field of
genetic engineering [8,9]. Application of these techniques
are underway in our laboratory as well as many others in
order to impart unique traits to livestock. These traits will
lead to improved production of food and fiber as well as
produce animals capable of making biopharmaceuticals
and nutriceuticals. We are reaching the point in livestock
genetic engineering where the technology is no longer the
limiting factor. We are now only limited by our imagina-
tions and the burdensome regulatory pathways for bring-
ing these products to the world’s population.
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